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ABSTRACT 
Isolated extramedullary relapse of chronic myelogenous leukemia (CML) after allogeneic stem cell transplant 
is rare. There is a case report of a child who developed a granulocytic sarcoma of the maxillary and sphenoid 
sinuses and lumbosacral spinal cord mass 18 months after allogeneic bone marrow transplant for CML. He was 
presented with per orbital edema and neurological deficit of lower extremities and a mass lesion was found on 
spinal cord imaging. No evidence of hematologic relapse was identified at that time by bone marrow histology 
or cytogenetic. The patient died 1 month later with a picture of pneumonia, left ventricular dysfunction and a 
cardiopulmonary arrest on a presumed underlying sepsis with infectious etiology. Granulocytic sarcoma should 
be considered in the differential diagnosis of mass lesions presenting after allogeneic bone marrow 
transplantation for CML, even if there is no evidence of bone marrow involvement. 
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INTRODUCTION 
Granulocytic sarcomas or as they were previously 
known chloroma are solid extra medullary masses 
composed of the blast forms of myeloid neoplasms. 
They could be manifestations of acute myelogenous 
leukemia (AML) or chronic myelogenous leukemia 
(CML) in blast crisis. They are very rare as an 
isolated presentation of relapse after allogeneic 
stem cell transplant (SCT), particularly in patients 
with CML.1,2 
We report here the case of a child who developed a 
granulocytic sarcoma of the maxillary, sphenoid 
sinuses and lumbosacral spinal cord as an isolated 
manifestation of CML relapse 18 months after 
allogeneic SCT. 
 
Case report 
An 18 month-old boy presented in January 1999/03 
with leukocytosis and a white blood cell count of: 
54400/mm3, RBC: 2.27 M/mm3, HGB: 9.1 g/dL, HCT: 
26.1 %, MCV: 115 fL, MCH: 40.1 pg, MCHC: 34.9 
g/dL, Platelet: 475000 K/mm3. 
Bone marrow aspiration and biopsy revealed 
granulocytic hyperplasia with an increased M/E 
ratio (20-30/1), basophilia and increased 
neutrophiles. Differential diagnosis considered at 
that time was leukomoid reaction and chronic 
myeloid leukemia. 
The immunophenotyping analysis by flowcytometry 
was as follows: 
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CD2 (0.4%), CD3 (12%), CD4 (0.1%), CD5 (2%), CD7 
(4%), CD10 (0.1%), CD13 (25%), CD14 (2%), CD15 
(60%), CD19 (1%), CD20 (1%), HLADR (12%), CD45 
(80%), CD34 (2%), CD117 (1%) which was consistent 
with an increased mature myeloid component and 
could be presumptive of CML or a reactive 
leukomoid reaction. 
These two entities could be differentiated by 
cytogenetic study of Philadelphia chromosome or 
BCR-ABL fusion gene detection. In a cytogenetic 
study of bone marrow despite absence of the 
Philadelphia chromosome and normal 46 XY 
karyotype, a positive BCR-ABL P210 fusion gene was 
detected by RT-PCR technique which was consistent 
with CML diagnosis. 
The patient was initially treated with hydroxy urea, 
ARAC and INF-α till 2005 while still in chronic phase 
the WBC count raised up and imatinib was started. 
Initially, there was a very good response to imatinib 
but due to the side effect of severe headache, 
imatinib was discontinued and he was again treated 
with ARAC, INF-α and hydroxy urea. 
Patient was under control till 2007/12, later 
because of another rise in WBC count imatinib was 
started again with a good response but it was 
always with severe arthritis (without warmness and 
redness) persisted in both elbows and right knee 
joint. On sonography of affected joints, effusion was 
detected along with an unbearable pain. Due to the 
increased ESR with the suspicion to septic arthritis, 
it was decided to perform an arthrotomy procedure 
on affected joints. Synovial fluid had fluidity with 
decreased viscosity. Bacterial culture of this fluid 
was negative. No evidence of septic arthritis was 
observed but empiric antibiotic therapy was 
continued. Severe arthritis pain due to 
administration of imatinib was relieved after 2 
weeks following drug discontinuation. On 
2007/12/02, while the patient was still in chronic 
phase, due to the side effects of imatinib, he was 
considered as a good candidate for allogenic 
peripheral blood SCT from his HLA- matched sibling 
donor. There had been a good response along with 
a slight graft versus host disease (GVHD) reaction 
which he received cyclosporine to control its side 
effects. 
On 2009/5, bone marrow biopsy, bone marrow 
aspiration and touch imprints showed megaloblastic 
changes in erythroid and myeloid cells. 
Megakaryocytic cells were normal in number and 
morphology, granulocytic component also was 
normal, while erythroid and monocytic components 
of bone marrow were increased. 
On 2009/6, analysis of STR of whole blood sample 
showed 65-70% chimerism. He received 2 DLI and 
later on short tandem repeat analysis of whole 
blood sample he had a 45-50% of chimerism. On 
2009/6, gimsa banding cytogenetic study showed 
46 XY t(9; 22) (q34; q11) + der(22) /46/XY 
corresponding with Philadelphia chromosome and 
an abnormal male karyotype accompanied by a 
clone of diploidy.3 
On 2009/7, the result of analysis for T3151 
mutation by RT PCR from Shariati Hospital 
laboratory was positive. On 2009/8, he was put on 
nilotinib. During this period, he always had 
periorbital edema and headache. On 2010/3, in 
brain CT scan, bilateral maxillary and sphenoid sinus 
mucosal thickening were observed. He also 
developed another complication on his lower 
extremities to the extent that he was not able to 
walk. On 2010/6, pelvic MRI showed enhancing soft 
tissue in presacral space in favor of tumoral mass 
and lumbosacral spine. MRI also showed inferior 
thecal sac enhancement in sacral canal in favor of 
malignancy. Due to recurrent sinusitis, periorbital 
edema on MRI technique and severe headache, 
sinusitis was diagnosed. On 2010/7, he went under 
sinus surgery with the probability of periorbital 
cellulites or fungal sinusitis. On 2010/7, paranasal 
biopsy showed respiratory type mucous infiltrated 
by rather monotonous large cells with high N/C 
ratio indented nucleolus with inconspicuous 
nucleoli which was very much consistent with an 
extramedullary malignant tumor (chloroma). On 
2010/7/10, BM aspiration revealed > 60% blasts, 
megakaryocytes normal in number and 
morphology, orderly erythroid maturation along 
with megaloblastic changes. Moreover, bone 
marrow trephine biopsy showed crushed bone 
trabeculla, 80% cellularity and monomorphic 
population of hematopoietic elements. No 
megakaryocytes suggestive of CML blastic crisis 
were noted. 
Evaluation of bone marrow biopsy myeloperoxidase 
in Shariati Hospital laboratory showed MPO (50%) 
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positivity and CD 34 (90%) positivity on blast like 
cells. IHC was diagnostic for blastic crisis of CML. On 
2010/8/19, he had cellulitis on left eye without 
tenderness and his chest x-ray on 2010/8/25 
showed cardiomegaly. 
On 2011/1, cytogenetic study revealed a 46 XY t(9; 
22) (q34; q11), del(10) (q21) /46, XY/ idem, add(2) 
(q23) compatible with Ph chromosome.4 
Sixty to eighty percent of CML cases develop 
secondary chromosomal aberration (CAs) during 
progression of disease which is usually reflective of 
the progressive nature of the disease. Peripheral 
blood lymphocyte karyotyping (PBLs) was also 
recommended to rule out the possibility of 
constitutional chromosome aberrations. 
On 89/4/12, he was again admitted to the hospital 
with severe headache and sinusitis. He had an 
upward gaze and epileptic seizure and metastatic 
meningitis was considered as a differential 
diagnosis but on normal CSF cytology and brain CT 
scan, this probability was almost ruled out. 
On 2010/7/3, on his last admission to Aliasghar 
Hospital, he had respiratory distress and 
tachycardia. O2 saturation was between 70-80% 
and he had a cardiopulmonary arrest due to left 
ventricular dysfunction. 
 
DISCUSSION 
   Leukemia-specific transcripts may be detected in 
the blood and bone marrow of individual CML 
patients for some months following allogeneic stem 
cell transplantation5,6,7 and their level may predict 
the risk of relapse.8,4 it was showed in one study 
that patients with no BCR-ABL transcripts detected 
between 3 and 5 months after transplantation had 
a probability of relapse at 3 years of 16.7%, whereas 
patients with low level and relatively high transcript 
levels had risks of relapse of 42.9% and 86%, 
respectively.4 When patients were categorized at 5 
years after transplantation on the basis of prior 
transcript pattern, the subsequent risk of relapse 
was related to the transcript pattern in the interval 
preceding the 5-year point.9 However, the study 
revealed that some patients had transcripts 
detectable at low level for long periods after SCT 
without obvious progression. Because the clinical 
significance of finding these transcripts at low level 
was not known, therefore a criteria was proposed 
for molecular relapse (MR) designed to exclude 
patients in whom transcripts were present only at 
low levels, regardless of how long such low levels 
might persist.9 
A chloroma is an extramedullary manifestation of 
acute myeloid leukemia; in other words, it is a solid 
collection of leukemic cells occurring outside of the 
bone marrow. Chloromas are rare; exact estimates 
of their prevalence are lacking but they are 
uncommonly seen even by physicians specializing in 
the treatment of leukemia. In general, chloromas 
must be regarded as an early herald of a systemic 
relapse, rather than as a localized process. In one 
review of 24 patients who developed isolated 
chloromas after treatment for acute myeloid 
leukemia, the mean interval until bone marrow 
relapse was 7 months (range: 1 - 19 months). 
Although extramedullary manifestations of relapse 
following allogeneic SCT for myeloid malignancies 
are not unusual, occurring in up to 20% of patients 
transplanted for AML,10 but granulocytic sarcomas 
presenting as an isolated manifestation of relapse 
of either AML or CML after allogeneic SCT are rare. 
In one retrospective multicenter survey, only 0.45% 
of 5284 patients transplanted for myeloid 
malignancies (AML, CML, or myelodysplastic 
syndrome) developed isolated granulocytic 
sarcomas.1 Granulocytic sarcomas were more 
frequent in patients transplanted for AML than in 
patients with CML or MDS (0.65% vs. 0.22%). In a 
retrospective analysis of a single center experience, 
only 5 patients presented with isolated granulocytic 
sarcomas out of 134 individuals transplanted for 
CML or AML.2 Only 2 of these patients had CML; 
both presented with sacral lesions (this report 
excluded isolated skin or CNS recurrences). Only a 
few other cases of isolated extramedullary relapse 
in patients treated with allogeneic SCT for CML have 
been reported. 11-15 Myeloid sarcomas occurred in a 
variety of locations including the spine, dural space 
and spinal nerve roots, lymph nodes, clavicle, orbit, 
skin and pericardium. Granulocytic sarcomas 
involving the sphenoid and maxillary sinus have not 
been reported previously in the post-transplant 
patients. Although the small number of patients 
reported make it difficult to draw conclusions, it has 
been hypothesized that the occurrence of 
granulocytic sarcomas in the absence of medullary 
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relapse of CML is more likely in the absence of 
GVHD, due to a lack of graft-versus leukemia 
effect.2 The presence of a stronger graft-versus- 
leukemia effect in bone marrow than in peripheral 
tissues has also been proposed.12 
Various treatment approaches have been used for 
isolated granulocytic sarcomas in the post-
transplant CML patient. Long-term outcomes have 
been reported for 12 patients. Two had long-term 
survival: one after local radiation alone1 and 
another after local radiation followed by a second 
allogeneic SCT.2 Four patients have been reported 
dead with hematologic relapse after receiving 
radiation and unspecified chemotherapy.1 Two 
patients achieved remission after donor lymphocyte 
infusion died at 3 months (one of GVHD and 
infection, one of GVHD and CNS relapse).11 One 
patient died of progressive local disease despite 
radiation and steroids.2 Three more patients have 
been reported dead within several months of 
infections after initially responding to radiation 
alone or (in one case) combined with cytarabine 
and thioguanine.12,13 
Donor lymphocyte infusion (DLI) is less effective in 
acute leukemia and other hematologic tumors. The 
appropriate role of DLI for post transplant relapse is 
still being defined. The high rate of durable 
complete remissions in CML has been determined. 
One could argue that DLI is the treatment of choice 
in relapsed CML. But in our patient in spite of two 
DLIs, appropriate response was not observed and 
the improper trend of laboratory and clinical 
manifestations was continued. The toxicity of DLI 
can be substantial and some relapsed CML patients 
may benefit from interferon-α therapy. 
Observations in humans have suggested strongly 
the existence of a GVL effect in human allogeneic 
BMT. Relapse rates in syngeneic BMT recipients are 
higher than in allogeneic BMT recipients. Allogeneic 
BMT recipients who do not develop GVHD relapse 
more frequently than allogeneic BMT recipients 
who do develop GVHD; and recipients of T-cell-
depleted BMT relapse more frequently than 
recipients of non-T-cell-depleted BMT. In addition, 
complete remissions have been observed in 
patients with relapsed disease after allogeneic BMT 
in association with flares of GVHD. 
Based on the apparent power of the GVL effect and 
its presumed mediation by donor leukocytes (T cells 
and/ or natural killer (NK) cells), leukocytes 
obtained from the original bone marrow donor 
have been infused into patients with relapsed 
malignancy after allogeneic BMT. Durable complete 
remissions have been reported in 50% to 70% of 
patients with chronic myelogenous leukemia (CML). 
Sporadic responses have also been observed in 
patients with other relapsed hematologic 
malignancies after allogeneic BMT. 
For better understanding of benefits and toxicities 
of DLI, relapsed patients after allogeneic HSCT 
should be assessed. Recipients of allogeneic BMTs 
who have relapsed may attain complete remissions 
when treated with transfusions of leukocytes 
obtained from the original bone marrow donor. The 
best therapy for patients with relapse after SCT 
remains to be defined, especially with the advent of 
imatinib as a very active drug in the treatment of 
chronic myelogenous leukemia (CML). 
 
CONCLUSION 
   Sarcoma should be a part of the differential 
diagnosis of patients who present with mass lesions 
after allogeneic transplant for CML, even in the 
absence of hematologic relapse. Imatinib mesylate 
is a small molecule tyrosine kinase inhibitor that has 
significant efficacy in the treatment of CML. 
However, it is likely that patients with CML will 
require prolonged and perhaps life-long therapy. In 
general, the side-effects of imatinib therapy have 
been mild to moderate, with the large majority of 
patients tolerating prolonged periods of therapy. 
However, a minority of patients are completely 
intolerant of therapy, while others are able to 
remain on therapy despite significant side-effects. 
Here, we described second case of fluid retention 
presenting as multiple joint effusions in a patient 
with advanced phase CML on high-dose imatinib. 
Although fluid retention including periorbital 
edema, pleural and pericardial effusions, as well as 
life-threatening cerebral edema has been previously 
described and attributed to imatinib, this is the 
second case of imatinib-associated polyarticular 
effusions. The first case was reported by Moore JC 
et al.16 Further work will be required to confirm a 
casual relationship between imatinib therapy and 
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this novel side-effect, as well as to determine the 
underlying pathophysiologic mechanisms for this 
side effect. 
Our patient while still in chronic phase underwent 
an allogeneic peripheral blood SCT from his HLA-
antigen matched sibling donor but bone marrow 
transplantation has better outcome if performed 
early in the course of the disease before treatment 
abandonment. 
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